Supplementary Information: Methods Details and Data
Though next generation sequencing can produce more accurate data with higher sensitivity 1 , we used microarray data because of the availability of a larger number of samples with adequate follow up information, which were retrieved from The Cancer Genome Atlas (TCGA) data portal (https://tcgadata.nci.nih.gov/tcga/) and also availability of an independent dataset, GSE20624 2 , as external test for the developed classifier. The Cancer Genome Atlas (TCGA) Research Network has improved our understanding in cancer biology through profiling and analyzing large numbers of human tumors. The resulting rich data offer a great opportunity to improve a coherent picture of variation across tumors 3, 4 . For the purpose of this study, Agilent Microarray (Agilent 244K custom gene expression) data of 1893 samples from published TCGA (http://tcga-data.nci.nih.gov/tcga/) representing six cancer types including breast: breast invasive carcinoma [ A list of human glycosyltransferase (GT) genes was retrieved through filtering several publicly available databases such as Kyoto Encyclopedia of Genes and Genomes database (KEGG/GENES) (http://www.genome.jp/kegg/genes.html), Carbohydrate-Active Enzymes database (CAZy) databases (http://www.cazy.org/), and literature search. KEGG/GENES is a pool of manually curated genes retrieved mainly from NCBI RefSeq [5] [6] [7] . Furthermore, CAZy provides an online and regularly updated access to family classification of CAZymes corresponding to proteins released in the daily releases of GenBank (ftp://ftp.ncbi.nih.gov/genbank/daily-nc) 8 . Supplementary Table 1 contains a list of human glycosyltransferase gene symbols with their Entrez numbers.
The expression dataset of glycosyltransferases was built through combining the TCGA expression datasets of six investigated cancer types (i.e. breast, brain, colon, kidney, lung and ovary) and further retrieving the expression of 210 glycosyltransferase genes from the combined dataset.
Batch effects are commonly observed systematic non-biological variation between groups of samples due to experimental artifacts, such as processing date, lab, or technician. Combining samples from multiple batches can cause the true biological variation in a high-throughput experiment to be obscured by variation due to batch 9 . However, the correlations of batch effects (technical and biological artifacts) with the outcome are common and critical to address 10 , correcting for batch effects when there is no significant effects may result in removing biological variation instead of the systematic non-biological variation due to batch 9 . Therefore, a simple test was performed to evaluate existing of batch effects in combined dataset with comparing box plots, QQ-plots and applying a t-test analysis before and after using an Empirical Bayes batch effect correction method, i.e. ComBat, implemented in 'sva' package 11 in R 12 . The result of this analysis clearly illustrated that no significant batch effects in the dataset (t-test p-value=0.5, Supplementary Figure 1a) and also there is no specific color grouping observed based on the batch effects in the principal component loading plot for PC1 to PC3 in the combined dataset (Supplementary Figure 1b) . However a significant grouping is observed while samples are colored based on the cancer type (Fig. 1a) confirming the batch effects do not stimulate cancer type grouping. In addition, separate principal component analyses were performed to investigate the batch effects in each TCGA cancer type while samples are colored based on the batch numbers and they have not shown any grouping based on the batch numbers in each cancer type (Supplementary Figure 1c) .
To separate cancer types based on the expression of glycosyltransferase genes, a principal component analysis was performed using 'psych' package 13 in R. Furthermore, a hierarchical average linkage clustering performed on GT genes and cancer types across the complete 1893 sample set using 'cluster' package 13 in R. The result of this analysis reveals that the expression profile of GT genes not only separates six cancer types but also represents a unique molecular entity with similarity to lung cancer for basal-like samples (TNBC, n=83, colored in black in the TNBC sidebar in Supplementary  Figure 2) , which is in line with the result of Prat and colleagues (2013) investigating the expression of 3486 most variable genes across six different cancer types from TCGA data 3 . To better understand how the expression of glycosyltransferase genes contribute to separation of cancer types from each other and to investigate dominant glycan-specific changes occur in carcinogeneic process of each cancer type, the expression of glycosyltransferase genes was compared among the cancer types and the association of glycosyltransferase genes to patient survival was studied. For this purpose, differential expression analyses were carried out using 'limma' package 14 in R. Genes with q-value > 0.005 and 2 fold change were considered as a differentially expressed gene in pairwise comparisons, while a 'decideTests' function in 'limma' package was used to assigning binary values (i.e. 1: up-regulated, -1: down-regulated and 0: not detected) to these genes. Finally, a gene in a specific cancer types was considered to be up-regulated if the median of all pairwise comparisons was 1 and it is down-regulated (-1) in none of the comparisons and wise versa (Supplementary Table 2 ). Correlation between patient survival and glycosyltransferase gene expression was performed using log rank test implemented in 'survival' package 15 in R, while samples in all cancer types were divided into two groups for each gene (0: samples that showed gene expression value above median and 1: below median), and then compared to each other in terms of overall outcome (Supplementary Table 2 ). In addition, Supplementary Table 3 shows the expression of glycosyltransferase genes between normal and malignant in various cancers in several studies.
Having established that the expression profile of glycosyltransferase genes are able to separate six cancers we explore the development of a GT gene classifier using shrunken centroid approach 16 in 'pamr' package (http://cran.r-project.org/web/packages/pamr) in R, which is able to identify cancer type from a random sample. Furthermore, 'caret' package 17 in R was used to rank the gene importance in a supervised learning model (pam model).
For the purpose of error estimation of training model (pam classifier) in the assignment of samples to the right cancer types, a 10-fold cross validation technique was carried out using 'pamr' package in R. In addition, internal and independent/external tests were carried out to evaluate the performance of the pam classifier using the expression of glycosyltransferase genes. For this purpose, the glycosyltranseferases' expression dataset was randomly split hundred times into training (70%) and test (30%) sets. Training sets were used to build a model, which were then applied to the testing sets. Finally, the median values were used to assign each sample to a specific cancer type. The result of this analysis was used for accuracy measurement calculation summarized in Supplementary Table 4 . Given a classifier and a sample, there are four possible outcomes: true positive, true negative, false positive and false negative. It is true positive if the sample is positive and it is classified as positive and it is false negative if it is classified as negative. It is true negative if the sample is negative and it is classified as negative and it is a false positive if it is classified as positive. Given a classifier and a set of samples (the test set), a two-by-two confusion matrix (also called a contingency table) can be constructed representing the dispositions of the set of samples, see Fawcett (2006) for more information and equations 16 . Furthermore, the ROC (Receiver Operating Characteristics) curve has been extensively studied and applied in medical diagnosis since the 1970s 18, 19 and the area under the ROC (AUC) 20 has become an important performance measure in this regard, since it is invariant to operating conditions 21 . The accuracy measures derived from a confusion matrix, the area under the receiver operating characteristic (ROC) curve and its confidence interval (CI) for internal test (Supplementary Table 4 ), clearly shows the potential of gene expression profiling of glycosyltransferase in tumor type identification/separation with high accuracy, sensitivity and specificity for all investigated cancer types.
Since training algorithms look for patterns in the training dataset, a classifier that relies on these spurious patterns will have higher accuracy on the training examples than it will on the whole population. Therefore, it is extremely critical to evaluate the performance of a classifier on an independent test set. For this purpose, training sets of previous test (internal test) have been used for an external (independent) test that examines 293 breast cancer samples existing in GPL1390 platform of GSE20624 2 . GSE20624 (GPL1390) data is not included in TCGA while it uses the same microarray platform with TCGA datasets, however, only 177 glycosyltransferase are common between training (TCGA based) and this dataset.
In terms of breast cancer subtyping, to provide a quantitative evidence for the prediction of a number of possible clusters within the TCGA breast cancer dataset, consensus clustering plus class discovery technique 24 was conducted using 'ConsensusClusterPlus' package 22 in R. Consensus clustering is a clustering framework that has been widely used for cancer subtyping. In this technique, the same clustering algorithm is applied multiple times to different subsets of the data and a consensus result is collected to better describe the similarities between samples 23 . The consensus Cumulative Distribution Function (CDF) and Delta area plots are the graphical representations to illustrate at what number of clusters, the CDF reaches an approximate maximum and at which k (number of groups) there is no significant increase in CDF curve, respectively. The result of consensus clustering analysis was graphically represented as heatmaps for the consensus matrices of k=2 to k=10. Accordingly, microarrays are placed in both rows and columns of the consensus matrices and consensus value ranges are colored by white to dark blue, indicating that samples never cluster together and always cluster together, respectively (Supplementary Figures 3a and b) . Furthermore, to group samples into subtypes based on the expression of glycosyltransferase genes, a k-means clustering was performed using 'cluster' package in R. Cluster significance was evaluated using 'SigClust' package 24 in R, and all class boundaries were statistically significant (Supplementary Figure 3c) . To investigate whether the identified groups (using k-means clustering), specific to breast cancer may represent clinically distinct subgroups of patients, univariate survival analyses (comparing subtypes, k=2 to k=10, with respect to the overall survival) was performed ( Supplementary Figure 3d) using 'survival' package in R, while previously identified normal-like 25 , metastatic samples and the samples with missing survival information in the corresponding patient were excluded (n=467). 
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Supplementary GALNT5  11227  PIGX  54965  B3GALT5  10317  GALNT6  11226  PIGY  84992  B3GALT6  126792  GALNT7  51809  PIGZ  80235  B3GALTL  145173  GALNT8  26290  PLOD3  8985  B3GAT1  27087  GALNT9  50614  POFUT1  23509  B3GAT3  26229  GALNTL1  57452  POFUT2  23275  B3GNT1  11041  GALNTL2  117248  POMGNT1  55624  B3GNT2  10678  GALNTL4  374378  POMT1  10585  B3GNT3  10331  GALNTL5  168391  POMT2  29954  B3GNT4  79369  GALT  2592  PYGM  5837  B3GNT5  84002  GBGT1  26301  RFNG  5986  B3GNT6  192134  GCNT1  2650  RPN1  6184  B3GNT7  93010  GCNT2  2651  RPN2  6185  B3GNT8  374907  GCNT3  9245  ST3GAL1  6482  B3GNTL1  146712  GCNT4  51301  ST3GAL2  6483  B4GALNT1  2583  GGTA1  2681  ST3GAL3  6487  B4GALNT2  124872  GLA  2717  ST3GAL4  6484  B4GALNT3  283358  GLB1  2720  ST3GAL5  8869  B4GALNT4  338707  GLT1D1  144423  ST3GAL6  10402  B4GALT2  8704  GLT25D1  79709  ST6GAL1  6480  B4GALT3  8703  GLT25D2  23127  ST6GAL2  84620  B4GALT4  8702  GLT6D1  360203  ST6GALNAC1  55808  B4GALT5  9334  GLT8D1  55830  ST6GALNAC2  10610  B4GALT6  9331  GLT8D2  83468  ST6GALNAC3  256435  B4GALT7  11285  GLT8D3  283464  ST6GALNAC4  27090  C1GALT1  56913  GLT8D4/GXYL  T2  727936  ST6GALNAC5  81849  C1GALT1C1  29071  GTDC1  79712  ST6GALNAC6  30815  CEECAM1  51148  GYG1  2992  ST8SIA1  6489  CHGN/GALNA  CT1  55790  GYG2  8908  ST8SIA2  8128  CHPF  79586  GYLTL1B  120071  ST8SIA3  51046  CHSY.2  337876  GYS1  2997  ST8SIA4  7903  CHSY1  22856  GYS2  2998  ST8SIA5  29906  CSGLCA.T  54480  HAS1  3036  STT3A  3703  DAD1  1603  HAS2  3037  STT3B  201595  DDOST  1650  HAS3  3038  UGCG  7357  DPAGT1  1798  KDELC1  79070  UGT1A6  54578 DPM1  8813  KDELC2  143888  UGT1A8  54576  DPM2  8818  KTELC1  56983  UGT2A1  10941  DPM3  54344  LARGE  9215  UGT2B10  7365  EIF2B3  8891  LFNG  3955  UGT2B11  10720  EIF2B5  8893  LOC152586  152586  UGT2B15  7366  EXT1  2131  MAN1A1  4121  UGT2B17  7367  EXT2  2132  MAN1A2  10905  UGT2B28  54490  EXTL1  2134  MAN1B1  11253  UGT2B4  7363  EXTL2  2135  MAN1C1  57134  UGT2B7  7364  EXTL3  2137  MAN2A1  4124  UGT3A1  133688  FLJ21865  64772  MAN2A2  4122  UGT3A2  167127  FUCA1  2517  MANBA  4126  UGT8 
N-glycans
Precursor synthesis
Lewis antigens
Sialyl Le(a) 99.87-100 *Diagnostic Power (DP) is determined by both its sensitivity and its specificity and it is the proportion correctly classified 74 . BRCA: breast invasive carcinoma (n=531), COAD: colon adenocarcinoma (n=154), GBM: glioblastoma multiforme (n=403), KIRC: kidney renal clear cell carcinoma (n=72), LUSC: lung squamous cell carcinoma (n=155) and OV: ovarian serous cystadenocarcinoma (n=578).
